Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 5

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 5
---
astroenterology (“GI”), Oncology, Rare Diseases and Vaccines. Among our six key business areas, the increase of these business areas was offset in part by a decrease in Neuroscience. The decrease in Neuroscience, which was partially mitigated by favorable foreign exchange rates, was largely attributable to continued generic erosion of sales of VYVANSE (for attention deficit hyperactivity disorder (“ADHD”)) in the U.S., which began following loss of exclusivity in August 2023. In addition, revenue outside of our six key business areas decreased mainly due to the decline in sales of AZILVA (for hypertension), which were JPY 8.8 billion (JPY -20.3 billion and -69.8% AER, -69.8% CER) following the entry of generic competitors in Japan beginning in June 2023.

<div align='center'>2</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Nine-month

Period Ended December 31, 2024 (Consolidated)

#### Revenue by Geographic Region
The following shows revenue by geographic region:

|                        |     |           |         |     |                  |         |     |          |       |     |          |      |   |     |     |      | Billion JPY or percentage |
|                        |     | FY2023 Q3 |         |     | FY2024 Q3        |         |     | AER      |       |     |          |      |   |     | CER |      |                           |
| Revenue:               |     |           |         |     | Amount of Change |         |     | % Change |       |     | % Change |      |   |     |     |      |                           |
| Japan                  |     |           |   342.6 |     |                  |   324.7 |     |          | -17.9 |     |          | -5.2 | % |     |     | -5.4 | %                         |
| United States          |     |           | 1,685.5 |     |                  | 1,841.4 |     |          | 155.9 |     |          |  9.3 | % |     |     |  3.0 | %                         |
| Europe and Canada      |     |           |   721.5 |     |                  |   795.